Combining FLT3 and SYK inhibition for AML
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
The evolution of CAR T-cell therapy
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
RESONATE, RESONATE-2 and HELIOS: three major clinical trials in CLL research